In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Quarterly Dealmaking Statistics, Q3 2016

A look at financing, M&A and alliance activity July–September 2016

Executive Summary

In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.

Advertisement

Related Content

Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Regeneron Partners NGF Antibody With Teva To Mitigate Risks
Intarcia Raises $215m As NDA For ITCA 650 Slips To Fourth Quarter
Could $639m Vitae Buy Give Allergan A New Autoimmune Focus?
Raptor Buy Bolsters Horizon's Orphan Business As Primary Care Foots The Bill
Moderna Prepares For mRNA Drug R&D Blitz With $474m In New Equity
Pfizer’s $14bn Medivation Buyout Shows How Far Pharma Will Go In Oncology
With Medivation, Pfizer Sees A Chance For More Combinations
Record CStone Funding Heralds New Era For China Startups
BMS Scoops Cormorant In $520M Immuno-Oncology Deal

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel